Schwab Network on $LLY

Channel profile →Sources cited by the channel: BFA and JP Morgan, Baird, Bank of America, Barclays, Berenberg, Bernstein, Bernstein, with a Jefferies target cut noted, Bilal Little, Bird (analyst firm), CEO, CEO Joe Dominguez, Caner, Citi, Citigroup, Citizens, Daiwa, Dan Deming and Michael Monahan, Dan Ies; Morgan Stanley, Dan Ives, Dan Ives and unnamed analysts, Deutsche Bank, Erit Research, Evercore ISI, Evercore ISI; Dan Ives, Goldman Sachs, JP Morgan Chase, JPMorgan, JPMorgan Chase, James Demerard of Wall Street Research, Jefferies, Jefferies, UBS and Citigroup, Jensen Huang; Dan Ives, KeyBank, Loop Capital, Mattie Natsson, Michael Saylor, Milius (analyst), Morgan Stanley, Northrop, Oppenheimer, Oppenheimer, Freedom Broker, Oracle, PFA analysts, Quantum CEO, RBC, Reddit CEO, Rothschild Redburn, SK Hynix, Seth, Tim Bigham, Tim and KG, Truist, UBS, Wall Street Journal, Wedbush, Wells Fargo, analysts, the street7 entries

Schwab Network has discussed $LLY in 7 videos since 2026-09-15. The latest, on 2026-11-16, was bullish.

2026-11-16Bullish
“Adam Coons On Defense; "No Touch" on NVDA, Avoiding HD and LOW Pre-Earnings”
AI summary · Eli Lilly is somewhat defensive; continued obesity-drug launches, with Retatrutide/GLP-3 next, may make it a game-changer that eliminates the competition. The speaker says LLY, like Google, has 10 to 20% upside potential, and both can outperform for different reasons and in different scenarios.

Share like Google that you liked. I mean, it saw that decline after the earnings, but it was in a somewhat upward trend. And Eli Lily. Do you think both of these stocks have a 10 to 20% upside potential?

As for Eli Lilly, it is once again a somewhat defensive stock , but the products they are putting forward and we see a continuation of the introduction of various obesity drugs.

I believe "Retatrotide" is next in the production line. Some people call it "GLP-3". This drug is likely to be a game-changer for them in this field, and may eliminate the rest of the competition.

2026-11-13Bullish
“PPI Mostly Cool, AI at "Crossroads" Amid NVDA CEO Search”
AI summary · Eli Lilly is a premium growth story: up 35% in a great year and one of the leaders of the healthcare run, it has capitalized on the biggest healthcare opportunity through its three leading GLP1 products, with favorable demographics a continued tailwind to a strong pipeline, so the premium valuation is justified.

Eli Lilly is one of those names on your list. I'm betting this is a bet on the GLP1 space, but walk us through your thesis here. Exactly. You know, Eli Lilly's had a great year up 35% and really one of the leaders of that healthcare run.

As you mentioned, they've been able to capitalize on, you know, really the the biggest opportunity right now in healthcare with their three leading GLP1 products.

2026-11-12Bullish
The Big 3: JNJ, LLY, AAPL
Subscribe or start a trial to unlock this step
2026-10-29Bullish
Thursday's First Moves: FTNT Falls After Earnings, CAT Tumbles, LLY Rises
Subscribe or start a trial to unlock this step
2026-10-28Bullish
Ghabour: Fed "Biggest Risk to Bull Market;" Bullish on MSFT, CRWD, LLY
Subscribe or start a trial to unlock this step
2026-09-18
40% of U.S. Adults to Use GLP-1s? Raul Shah on LLY, NVO & Weight Loss "Mania"
Subscribe or start a trial to unlock this step
2026-09-15Bullish
Tuesday's First Moves: LLY & ETSY Upgrades, PLAY Plunges After Earnings
Subscribe or start a trial to unlock this step
5 earlier entries need a subscription
The latest 2 are free to read. Earlier entries keep their date and direction; the text unlocks with a subscription.
Subscribe to read all 5 earlier takes